Avoro Capital Advisors LLC
Avoro Capital Advisors LLC reported 30 holdings worth US$9.69B as of Sep 30, 2026 (Form 13F)
As of Sep 30, 2026 · Filed Nov 16, 2026
Avoro Capital Advisors LLC reported 30 holdings worth US$9.69B as of Sep 30, 2026. Largest: United Therapeutics Corporation, Krystal Biotech, Inc. and argenx SE. Filed Nov 16, 2026 (Form 13F).
- Holdings
- 30
- Value as reported
- US$9.69B
The filing in full
| Company | Shares | Value as reported | % of portfolio |
|---|
| United Therapeutics Corporation | 2.76M | US$1.49B | 15.4% |
| Krystal Biotech, Inc. | 2.89M | US$961M | 9.9% |
| argenx SE | 1M | US$959M | 9.9% |
| Madrigal Pharmaceuticals, Inc. | 1.83M | US$924M | 9.5% |
| Kymera Therapeutics, Inc. | 7.47M | US$836M | 8.6% |
| Arrowhead Pharmaceuticals, Inc. | 11M | US$720M | 7.4% |
| Revolution Medicines, Inc. | 2.15M | US$440M | 4.5% |
| Cytokinetics, Incorporated | 4.9M | US$323M | 3.3% |
| Definium Therapeutics, Inc. | 7.05M | US$268M | 2.8% |
| Structure Therapeutics, Inc. | 6.56M | US$205M | 2.1% |
| Xenon Pharmaceuticals Inc. | 5.5M | US$205M | 2.1% |
| Vera Therapeutics, Inc. | 5.63M | US$182M | 1.9% |
| Celcuity Inc. | 1.5M | US$119M | 1.2% |
| Taysha Gene Therapies, Inc. | 23.9M | US$116M | 1.2% |
| Ocular Therapeutix, Inc. | 12.4M | US$95M | 0.98% |
| Hemab Therapeutics Holdings, Inc. | 1.89M | US$58.4M | 0.60% |
| Viridian Therapeutics, Inc. | 2.5M | US$51.5M | 0.53% |
| Septerna, Inc. | 1.3M | US$50.9M | 0.52% |
| Abivax SA | 488K | US$48.3M | 0.50% |
| Scribe Therapeutics Inc. | 2.6M | US$47.8M | 0.49% |
| Sensei Biotherapeutics, Inc. | 1.41M | US$41.9M | 0.43% |
| Avalo Therapeutics, Inc. | 2.38M | US$36.5M | 0.38% |
| Braveheart Bio, Inc. | 1.25M | US$25.4M | 0.26% |
| Whitehawk Therapeutics, Inc. | 2.85M | US$10.7M | 0.11% |
| Lexeo Therapeutics, Inc. | 525K | US$1.77M | 0.02% |
| Damora Therapeutics, Inc. | 0 | US$0 | 0.00% |
Source
Download original · View original at SEC
Related